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clinical research and accordingly develop a strategic plan to this 
effect.(4,5) In order to be able to institute such a plan, it is essential 
that the various opportunities and challenges be recognised. 
ReseaRch agenda foR caRdiovasculaR             
disease in afRica
Africa is a continent of great diversity. On the one end, it consists 
of extremely poor and remote rural regions with traditional 
existences, while on the other end, there are highly industrialised 
cities populated with people following an urban westernised 
lifestyle. As a result of this multi-ethnic population, different stages 
of the epidemiologic transition are evident across Africa. 
According to the literature, rheumatic heart disease, cardiomyo-
pathy and tuberculous pericarditis are the major causes for heart 
disease in the African population.(6) This leads to a high mortality 
and morbidity in young people, crippling the economy by debilita-
ting and killing the productive population of adults, and leaving an 
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intRoduction                                                              
According to Whitworth, health research is essential for the 
development of low- and middle-class countries(1) and, in a 
developing country like South Africa, contributes to overall 
healthcare “by identifying the causes of problems, facilitating 
diagnosis, improving the efficiency and effectiveness of care, and 
promoting good policy-making. It also supports the training of 
competent health professionals of all kinds, and contributes to 
global knowledge about locally, as well as generally, prevalent 
diseases in terms of prevention and treatment”.(2) Although there 
have been a number of initiatives designed to strengthen research 
capacity in Africa over the past few years, the success thereof is 
difficult to measure. The Thomson Reuters Global research report 
attempts to do so by reporting the volume of scientific publications 
produced by various countries over the continent. Not surprisingly, 
the six leading African countries by output (namely South Africa, 
Egypt, Nigeria, Tunisia, Algeria and Kenya) also correspond with 
four of the leading countries in terms of gross domestic product 
(GDP). However, it is clear that the continent’s research output 
is still small and needs to be further addressed.(3) A recent edition 
of the Lancet highlighted the need for South Africa to prioritise 
africa is a continent of great diversity and consists of 
extremely poor and remote rural regions characterised by 
traditional existences, as well as highly industrialised cities 
populated with people following an urban westernised 
lifestyle. this has resulted in an interesting presentation 
of diseases involving the cardiovascular system. on the 
one hand, rheumatic heart disease, cardiomyopathy and 
tuberculous pericarditis remain prevalent and under-
researched among the black african population, while on the 
other hand, cardiovascular disease and its associated risk 
factors are starting to emerge and currently account for 10% 
of all deaths. clinical trials play a crucial role in raising public 
awareness and promoting good policy-making; however, 
the continent’s research output is still small. opportunities 
and challenges facing african researchers need to be 
identified in order to develop a strategic plan for the way 



















increasing number of orphans in the care of the poor and weak 
elderly populations.(7) A great amount of original research is needed 
in cardiac disorders that are either common or rare in the black 
African population. Implementing preventative strategies for these 
conditions depend on social changes, improving primary healthcare 
services, elimination of poverty, better housing and an enhanced 
knowledge of the disease process through research and develop-
ment programmes that are currently constrained by staffing and 
budgetary restrictions.(6)
Studies in the 1970s to 1980s suggested that the prevalence of 
cardiovascular disease(CVD) was low in the black African popu-
lation.(8) However, CVD has since become an ever-present cause 
of morbidity and a leading cause of mortality in South Africa, 
Zimbabwe and the rest of sub-Saharan Africa, partly due to the 
presence of determinants and risk factors in these societies.(9,10) 
In fact, CVD is the second highest cause of death in most African 
and low-income countries, accounting for 10% of all deaths.(11) It is 
estimated that this burden will double from 1990 to 2020.(11) The 
effects of CVD are well documented in developed countries. 
However, reliable data describing the burden of this epidemic in 
developing countries associated with a high prevalence of mal-
nourishment and infectious diseases is scant. Currently, developing 
countries contribute a greater share to the global burden of CVD 
than developed countries; it has been estimated that 5.3 million 
deaths were attributed to CVD in developed countries in 1990 
compared to 8 to 9 million deaths in developing countries.(12)
In South Africa, CVD, diabetes, respiratory disease and cancer have 
been heralded as the “silent killers” of this socially and culturally 
diverse population. One in three men and 50% of all women are 
overweight.(13) Increasing urbanisation and resultant unhealthy 
lifestyles, lead to the appearance of various chronic diseases of 
lifestyle risk factors such as hyperlipidaemia, diabetes, atherosclero-
sis, obesity, hypertension and an increasing tobacco addiction. 
Amongst these, CVD is the most common cause of death for 
people age 45 and older.(13)
The public health system, already under pressure to manage the 
acute care of infectious diseases such as HIV/AIDS and tuberculosis, 
battles to deal with the effective treatment and prevention of 
CVD, diabetes and cancer due to limited financial resources. This, 
combined with limited public awareness of these conditions, results 
in these diseases often going unnoticed. Clinical trials play a crucial 
role in raising public awareness and educating the public about 
identifying risk factors and early signs of chronic lifestyle diseases.(13)
lack of capacity foR health ReseaRch            
Undertaking clinical trials in Africa is far from easy. For a start, many 
of the African countries have an environment that is not conducive 
to research and “the legislative framework has not kept pace with 
trends in research, such as genetics research, ethical conduct of 
clinical trials, material exchange, and intellectual property rights”.(1) 
Inclusion of large numbers of patients of African origin is the ideal 
objective. This may contribute to exploring possible genetic dif-
ferences and therefore different efficacy and adverse event profiles 
in these patients. It has been shown in Africans from South Africa 
that their Lp(a), known to be associated with increased CVD, 
differs from that of other ethnic groups, including Caucasians and 
Africans.(14) In addition, there are a number of other factors that 
need to be considered:
 ■ In most medical schools, including those in South Africa, 
specialist training “traditionally focuses on clinical experience 
and skills accrual, and lacks a research focus”.(15)
 ■ Most academic tertiary units struggle to remain academically 
active and in some countries, such as South Africa, this has been 
attributed to a cumulative disinvestment in publicly funded 
research programmes. For instance, in South Africa, the health 
departments of provincial governments no longer contribute to 
research, the National Health Laboratory Service does not 
provide any discount for research tests, and the Medical 
Research Council, despite having a mandate for maintaining and 
developing the country’s research capacity, is chronically 
underfunded.(5,16)
 ■ The global nature of science and lack of career paths to attract 
and retain good researchers has resulted in many of the top 
African researchers moving to countries where their efforts 
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and talents are better rewarded and better appreciated.(1) 
According to ASSAf, the clinical research force is ageing and has 
been steadily declining in numbers since the early 1990s.(2) 
In this age of evidence-based medicine, clinical guidelines and health 
policies should ideally be based on well-run, local, randomised 
controlled trials. 
African governments need to provide the basic infrastructure for 
health research.(1) There is increasing interest in and recognition of 
the crucial importance of strengthening the research capacity for 
health in Africa and to date there are several initiatives and schemes 
that have recently or are currently being developed.(1,17) These 
include:
 ■ The African Health Research forum and University Science, 
Humanities and Engineering Partnerships in Africa (USHEPiA – 
see http://www.ushepia.uct.ac.za/bg.htm).
 ■ The European and Developing Countries Clinical Trials 
Partnerships (EDCTP) Networks of Excellence (see http://
www.edctp.org). 
 ■ The European-Union-funded Network for the Coordination 
and Advancement of sub-Saharan Africa-EU Science and 
Technology Cooperation (CAAST-Net – see http://www.
caast-net.org).
 ■ The Health Research Capacity Strengthening (HRCS) initiative 
partnership between DIFD, IDRC, and the Wellcome Trust 
(see http://www.idrc.ca/cp/ev-106713-201-1-DO_TOPIC.html.
 ■ The Neglected Tropical Diseases (NTD) fellowship scheme, 
supported by a consortium of European Foundations (see 
http://www.ntd-africa.net).
 ■ The Netherlands-African partnership for capacity development 
and clinical interventions against poverty-related disease, the 
Netherlands Organisation for Scientific Research (see http://
www.nwo.nl/naccap). 
 ■ The Royal Society UK science networking scheme with 
Ghana and Tanzania (see-http://www.royalsoc.ac.uk/funding.
asp?id=6816).
 ■ The Wellcome Trust African Institutions Initiative (see http://
www.wellcome.ac.uk/News/Media-office/Press-releases/2009/
WTX053482.htm).
While these various initiatives and schemes are headed in the right 
direction, they may fail to achieve their aims because of no 
coordination and duplication of effort.(1) The EDCTP, for instance, 
certainly did not get off to an auspicious start with the ousting of its 
executive director at the first annual forum and rumblings of 
discontent among grant applicants with regards to poor admini-
stration.(18) Lessons from other sectors such as agriculture and 
education also need to be sought and discussed.
lack of funding foR clinical ReseaRch        
In 2007, the African Union members pledged to spend 1% of their 
GDP on research and development.(19) According to ASSAf, 2% of 
GDP is the necessary minimum investment in indigenous science 
and technology development, with health research receiving at 
least 20% of this amount.(2) Currently in South Africa, 10.8% of all 
government expenditure is on health and, according to the National 
Health Expenditure Review in 1991/1992, it was estimated that 
about 1.1% of this was spent on research. South Africa is spending 
more on research and development than before, but it is still 
considerable less than 1% of GDP. 
Clinical researchers are thus being left with no alternative but to 
rely on funding from the pharmaceutical industry (whose pre-
dominant interest is aimed at profitable areas such as chronic 
diseases of lifestyle, mental illness and allergies) and international 
donors (whose predominant interest is HIV and tuberculosis).(16) 
The overall effect of this is that the local needs of the countries 
are being bypassed. Governments from these nations accordingly 
need to start recognising that research funds are a “good 
investment”.(1)
pRotection of paRticipants                                    
According to section 12(2)(c) of the constitution of South Africa 
Act, No 108 of 1996: “Everyone has the right to bodily and 



















psychological integrity, which includes the right…not to be sub-
jected to medical or scientific experiments without their informed 
consent.”(20) In Africa, where cultural, political and racial factors 
give rise to third world conditions, special attention should still be 
given to obtain informed consent from rural or vulnerable com-
munities. In South Africa, for instance, a local version of Good 
Clinical Practice, namely South African Good Clinical Practice 
guidelines (SAGCP), is used in conjunction with the International 
Conference of Harmonisation (ICH) version. Much of the content 
of SAGCP is aimed at promoting safe research among vulnerable 
populations and ensuring that researchers are held accountable. 
This is achieved by:
 ■ Incorporating a separate section dedicated to “Research 
requiring additional attention” (Section 2.3) including research 
involving, inter alia, collectivities, indigenous medical systems, 
vulnerable communities, minors, mentally disabled people, HIV/
AIDS, and women and foetuses, and 
 ■ Ensuring that principal investigators are South African based 
scientists (Section 3.1).(21)
It is also essential that all clinical research involving human 
participants is approved by an independent research ethics com-
mittee. Ethical and regulatory issues, such as possible inadequacy 
with regards to regulatory and ethical control and overview, and 
varying competency of local ethics committees are frequently cited 
as problems characterising these bodies in developing count- 
ries.(22-24) Such concerns were highlighted recently with regards to 
criticism of a clinical trial in South Africa that was published in 
the February 2010 edition of the New England Journal of Medicine, 
namely the SAPIT study.(25) The ensuing blog on the website of 
the Bioethics Forum of the Hastings Centre stated that this trial 
had violated both ethical study design and the Declaration of 
Helsinki, and insinuated that research ethics review and training in 
South Africa was substandard.(26) These findings were upheld by 
Boulle.(27) In defence, Cleaton-Jones argued that “at a structural 
level research ethics review in South Africa is in many cases 
equivalent to the US institutional review board (IRB) and Office 
for Human Research Protections (OHRP) oversight system, is 
wider reaching, and has no exclusions”.(28) Nonetheless, training 
for research ethics committee members is essential and remains a 
global issue – especially in the context of third world countries.
language baRRieR                                                          
Africa, with its rich cultural heritage, diverse population and wealth 
of traditional knowledge has a lot to offer modern science, but 
much is lost due to language constraints. Conversely, this also poses 
a problem when science cannot be translated into local languages. 
In South Africa, for instance, there are 11 official languages and a 
population consisting of black Africans 79%, white 9.6%, coloured 
8.9% and Asian 2.5%.(13) Translations are usually required for the 
informed consent forms and patient information brochures, how-
ever English is acceptable for the clinical protocols, CRFs and 
Investigators Brochures.(13) 
The translation of African languages and practices results in a great 
deal of local knowledge being lost, and leads to farmers and rural 
communities being excluded from the modernisation of science 
and technology, as there are no local terminology or expressions to 
explain or translate the two concepts.(19) Zimbabwean scientists 
are currently compiling a Shona dictionary, a language currently 
being spoken by 9 million Zimbabweans.(19) One of the problems 
with this dictionary is the inability of literal translations to ade-
quately explain an entire concept. Furthermore, translations can 
only succeed when sufficient funding is available.
infoRmed consent                                                    
In African communities, important concepts of informed consent 
such as risk-benefit ratio, fair treatment of participants and voluntary 
participation, are interpreted in a different way.(29) However, the 
recruitment of participants in clinical trials remains essential to the 
success of the trial. In third world countries, participant recruitment 
is complicated by political, ethical, social and scientific concerns, 
especially when research is funded by affluent countries.(29) Ac-
cording to the Declaration of Helsinki, when undertaking “medical 
research on human subjects, considerations related to the well-
being of the human subject should take precedence over the 
interests of science and society”.(30) The process of individual 
informed consent of subjects is, accordingly, crucial.
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Subjects from developing countries are regarded as excellent can-
didates for clinical trials as people in these communities tend to 
be poor, malnourished, illiterate and sometimes desperate. The 
Nuremberg Code states that “voluntary consent of the human 
subject is absolutely essential. This means that the person involved 
should have legal capacity to give consent, should be so situated 
as to be able to exercise free power of choice, without the inter-
vention of any element of force, fraud, deceit, duress, overreaching, 
or other ulterior form of constraint or coercion”.(31) However, in 
many African countries, personal choice is particularly limited. In 
particular, in African cultures the concept of personal choice or 
free power of choice (collectively named personhood) is vastly 
different from western civilisation. A person’s tribe, village or social 
group defines ones personhood. In other words, persons exist only 
in relation to other persons.(29) This complicates the process of 
obtaining individual informed consent, as each individual member of 
the community sees the community as themselves. Investigators 
should thus shift the consent process from individual consent to 
the family or community. In some cases, investigators would need 
to approach the community’s elders for their consent before 
seeking consent from an individual.
According to African tradition, obtaining individual consent requires 
that a member of the family also gives consent to participate in 
medical research. This might impose a new challenge with the 
introduction of a waiting period. This waiting period can often be 
problematic as a result of the need for the individual to return to 
the region, with added transport costs and a loss of time.(29) 
Furthermore, the possibility of misinterpretation of the consent 
form poses a real threat, and it may result in no permission being 
granted to enter the study.
Informed consent forms (ICF) often present highly complex 
information that needs to be understood by patients. It is import-
ant that subjects truly understand specific elements in the ICF, 
including the purpose of the study, the randomisation process, and 
risks and benefits in participating, and that participation is voluntary. 
Complexity of the consent form has been shown to be a major 
barrier to comprehension for many patients. Examples of these 
CArdiovAsCulAr CliniCAl TriAls in AfriCA
barriers include excessive length of the form, inadequate time to 
read the consent, the reading level, and the format and layout of 
the form.(32) These obstacles are especially problematic for subjects 
with low literacy skills. According to a recent study conducted in 
South Africa, the readability levels of 84 ICFs used over a period of 
ten years were examined. The mean ±standard deviation (SD) 
Flesch–Kincaid Reading Ease score for the 84 ICFs was 46.60 ±5.62 
(range 33.2–65.6). The mean ±SD grade level was 12.13 ±1.8 
(range 8.3–14.9) using the Flesch–Kincaid formula and 13.96 ±1.22 
(range 10.3–16.6) using the Gunning-Fog index. The recommended 
grade 8 readability level was only found in 1.2% of all the ICFs 
assessed.(32) 
It is the investigator’s responsibility to ensure that a potential trial 
subject is competent to fully understand the informed consent. 
A study conducted in a cardiology research unit in Cape Town, 
South Africa demonstrated that, despite adequate time and expla-
nations being provided by researchers, participant understanding 
of certain research terminologies, such as randomisation and 
placebo, were poor.(33) Thus more time and effort are needed for 
participants with lower levels of education and/or little experience 
of research or medical contexts.  A person is deemed competent if 
“able to understand a therapy or research procedure, to deliberate 
major risks and benefits, and to make a decision in light of this 
deliberation”.(29)
Due to malnourishment and poverty, people in developing 
countries do not have equal opportunities for education and are 
commonly considered illiterate or uneducated. These people are 
classified as vulnerable research subjects because they often lack 
the capacity or competency to give informed consent. People in 
vulnerable communities often do not understand the complicated 
protocol requirements or procedures, which results in them being 
unable to decide whether or not to participate in a trial. 
oppoRtunities and conceRns RegaRding          
globalisation of clinical ReseaRch
In recent years, there has been a significant geographical shift in 



















the United States and Western Europe, to developing countries, 
including those in Africa.(22) Tracking research in Africa remains 
difficult as there are few published studies reporting this. ASSAf 
reports that only 1% of the total spent on clinical trials worldwide 
is spent in Africa, with 80% of that being spent in South Africa.(2)
South Africa has seen a consistent growth in clinical research 
emanating from contract research organisations and pharmaceu-
tical companies. In 2001, an estimated 400 clinical trials were being 
conducted in South Africa with expenditure in excess of USD 150 
million.(13) In 2008, it was estimated that this figure has increased 
to approximately R2.2 billion.(34) In fact, a total of 1 098 trials are 
currently registered in the South African National Clinical Trials 
Register (SANCTR), with cardiovascular diseases and diabetes 
mellitus accounting for just over 10%.(35) Key factors for the 
growth in clinical trials in South Africa include a history of high 
quality medical research, a high burden of disease and relatively 
drug-naïve populations.(36)
There are a number of concerns associated with this policy of 
globalisation, including:
 ■ Lengthy regulatory approval times.
 ■ Concern over the standard of data.
 ■ Lack of confidentiality.
 ■ Dodgy recruitment methods.
 ■ Inexperienced and inadequate ethics committees.(37)
There have also been numerous instances where pharmaceutical 
companies have attempted to pursue clinical trials in developing 
countries which would not be considered ethical or practical in a 
developing country.(38) A good example of this is the Trovan 
meningitis study in Nigeria during 1996.(23) Emanuel has identified 
three controversial issues with regards to the conduct of clinical 
trials in developing countries that need to be addressed, namely the 
standard of care to which investigational treatments should be 
compared, the “reasonable availability” of proven interventions 
demonstrated to be beneficial during the study, and the “quality of 
the informed consent” process.(39) However, there have been 
numerous other concerns that have been raised and include:
 ■ Personnel and site issues, such as shortage of experienced, 
trained site staff. Very few research centres are adequately 
equipped to perform clinical trials, while those few who are, 
remain to be oversubscribed. This necessitates the need for 
developing an infrastructure to conduct research in Africa. 
Partnerships, such as the EDCTP, have been accordingly 
instituted to fund research in developing countries, particularly 
in Africa, that contribute to the development of affordable 
prophylactics and drugs for HIV/AIDS, tuberculosis and 
malaria.(18) The EDCTP believes that the best approach in 
training the new generation African scientists is training on 
the job, involving them fully in the planning and execution of 
the trial. In addition, challenges, such as unreliable electricity 
supplies and inaccessible roads, are a reality in rural and remote 
sites.(38) These can impact heavily on the conduct of the trial 
and hence the integrity of the data. In some cases, safety of site 
personnel can also be problematic.
 ■ Ethical and regulatory concerns, as discussed above.
 ■ Population diversity: The increasing environmental, cultural and 
ethnic diversity of the research participants may pose problems 
in reaching conclusions – for example, angioneurotic oedema 
secondary to ACE-inhibitors is more common in African 
Americans than in white patients.(22,38) In addition, it is important 
that sponsors obtain the commitment, support and under-
standing of local leaders, health workers and their customs.(38) 
Care must be taken to ensure that the project is not per- 
ceived as “exploitative”.(38,39) 
 ■ Suitability of clinical research to the population: There are 
ethical concerns about researching drugs in a community in 
which the sponsor has no intention of marketing the drug. 
Medication that is affordable in first world countries is often 
too expensive for the majority of patients in developing 
countries; relevant strategies need to be researched for these 
countries.(38,40) In addition, historically, uneducated, socio-
economically-deprived populations were “targeted for high-risk 
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research, whereas promising research was offered in more 
privileged individuals.(39)
 ■ The potential vulnerability of the population group must be 
recognised and not exploited. In some instances, remuneration 
for study participation may be excessive.(40,41) In addition, trial 
participation may be the only way in which patients can gain 
access to medical services and medication to which they 
would otherwise be denied. This finding was confirmed in a 
South African study where more than 90% of respondents 
listed this as a reason for volunteering for a clinical trial.(42) 
 ■ Other local issues, such as the use of over-the-counter con-
comitant medications, particularly local herbal remedies, which 
can cause unexpected drug interactions and adverse effects.(38)
Other issues raised by Glickman include: “transparency of clinical 
trial results” and subsequent “protection of publication rights and 
access to trial data”, and “genomic information in drug develop-
ment”.(40) Despite these challenges, there are a number of signs that 
developing countries are meeting the desired quality of performance. 
Yusuf has analysed the performance of developing countries in a 
number of international randomised control levels and demon-
strated that the quality of data, patient attrition and overall study 
performance was on par with first world countries.(38) In South 
Africa, for instance, a total of 37 sites were audited by the Food 
and Drug Administration (FDA) of America from 1994 to 2009.(43) 
The most common deficiencies were “failure to follow the 
investigational plan” (15 sites) and “inadequate and inaccurate 
records” (8 sites). There was a single inspection in 1997 that 
resulted in an “Official Action Indicated” report being generated, 
with the deficiency being cited as “inadequate and inaccurate 
records”. These findings are shown in Table I, and are better than 
many FDA inspection findings from developed countries.
conclusions                                                                    
Clinical research in Africa is in a state of crisis and a strategic plan 
needs to be developed and implemented. In many ways, South 
Africa appears to be leading the way with regards to research 
output on this continent but even in South Africa there has been 
almost 20% decrease in publications between 1990 to 1994 and 
1996 to 2000.(5) The long-term future and sustainability of clinical 
research in Africa depends on many factors, and are adequately 
summarised in the brief of the ASSAf council;(2) namely
 ■ The creation of a national culture conducive to clinical research 
with the acceptance and promotion of clinical trials as the basis 
for evidence-based medicine,
 ■ Equipping and encouraging medical students to realise the 
importance of clinical research and evidence-based medicine in 
delivering effective healthcare,
 ■ Improving the accessibility and provision of funding for investi-
gator-driven clinical research,
 ■ Ensuring the practice of ethically acceptable clinical research 
with adequate protection of the rights and safety of research 
participants, and
 ■ Promoting the interaction and collaboration of government, 
parastatal institutions, academia and industry with regards to 
research efforts and capacity-building. 
In addition, initiatives aimed at improving the education of the 
whole population regarding Western medicine must be stepped up 
in order to allay fears among some ethnic groups that Western 
medicine may be harmful and to provide reassurance that the aim 
of these trials is to promote the health of everyone, including the 
people of Africa.    
table 1:  Classification of fdA inspection findings at south African 
trial sites
 no action voluntary official  total 
 indicated  action  action
  indicated indicated 
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